We wrote about ResMed (RMD) a few months ago in Livewire, warning of the downside Michael Gable Fairmont Equities
From @morgans following the Resmed (RMD) result on Friday: Resmed (RMD, Hold, Price Target A$5.40) - 2QFY14 earnings were below expectations as volumes and... Livewire Equities Livewire
